Parnell Veterinary Pharmaceuticals

Parnell Veterinary Pharmaceuticals is a leading global veterinary pharmaceutical company with a strong track record in research and development, clinical science, and regulatory processes. With a recent FDA accreditation of its sterile manufacturing facility in Sydney, Australia, the company is positioned to swiftly bring innovative solutions to the market. Parnell also stands out with its unique digital technology solutions that integrate with its innovative products to offer veterinarians and animal owners superior animal health solutions. The company has a market-leading portfolio of products for companion, performance, and production animals, including innovative cattle breeding programs and osteoarthritis solutions for dogs. Moreover, Parnell has an impressive pipeline spanning anesthesia, anti-microbials, orthopedics, and laminitis. Founded in 1968 and headquartered in the United States, Parnell's commitment to the core values of Professionalism, Excellence, and Teamwork is reflected in its strong focus on personal and professional development. The company rewards hard work and talent with opportunities for growth. Parnell's most recent investment was a Post-IPO Debt investment on 01 February 2021, with White Oak Healthcare Finance as the investor. The company's dedication to growth, innovation, and its global impact in the Biotechnology, Health Care, and Pharmaceutical industries make it an exciting prospect for venture capitalists.